| abstract |
The object of the present invention is to provide formulations containing improved antibody molecules. By altering the amino acid sequences of the variable and constant regions of tocilizumab, a humanized anti-IL-6 receptor IgG1 antibody, the antigen neutralizing ability is enhanced and the pharmacokinetics are improved to reduce the administration frequency and continue It is intended to provide a preparation comprising a second generation molecule that exhibits a therapeutic effect, improves immunogenicity, safety, and physicochemical properties (stability and uniformity) and is superior to tocilizumab. The formulation preferably contains arginine as a stabilizer and is provided in solution or solid form. |